Studies camostat, a kidney-related drug, in people with chronic kidney disease

Trial details

Who runs it

Odense University Hospital

Trial code

NCT06794593EU 2023-508516-34-00

Record updated

27 January 2025

Original description

This clinical trial aims to evaluate the effects of Camostat Mesylate, a serine protease inhibitor, in patients with chronic kidney disease (CKD) and proteinuria. Proteinuria accelerates CKD progression and increases cardiovascular risks. By inhibiting serine protease activity and tubular complement activation, camostat may mitigate progressive kidney injury, potentially improving clinical outcomes.Read full original descriptionShow less

Effect Camostat for Kidney Protection in Chronic Kidney Disease

This clinical trial aims to evaluate the effects of Camostat Mesylate, a serine protease inhibitor, in patients with chronic kidney disease (CKD) and proteinuria. Proteinuria accelerates CKD progression and increases cardiovascular risks. By inhibiting serine protease activity and tubular complement activation, camostat may mitigate progressive kidney injury, potentially improving clinical outcomes.

This is an interventional, non-randomized, open-label pharmacodynamic trial that includes CKD patients with proteinuria and healthy controls. This approach has been chosen as the trial serves as a pilot study, aiming to investigate a novel treatment target in CKD patients. Including healthy controls allows a comparison of the effect of Camostat Mesilate on normal physiology versus CKD with proteinuria.

Participants will:

* Follow a standardized sodium diet of 150 mmol/day for 8 days. * Receive oral Camostat Mesilate (200 mg thrice daily) for four days (day 5-8 on the diet). * Provide blood and urine samples, record blood pressure, and undergo body composition measurements at baseline, during intervention, and at study completion.

The primary effect parameters are urine sodium and water excretion, body water content/weight, and home blood pressure. Secondary endpoints are tubular complement activation, urine protease activity, ENaC activation, 24-hour urine albumin excretion, and plasma concentrations of renin, angiotensin II, aldosterone, and NT-proBNP.

Inclusion: Age ≥ 18 years; A clinical diagnosis of CKD of any course and meet the following criteria at screening:; eGFR ≥ 30 ml/min/1.73m2; U-ACR ≥ 300 mg/g; Stable antihypertensive treatment 2 weeks before start of investigated medical drug (IMP) and maintain this treatment throughout the study; Office blood pressure at the screening session should be >120/70 mmHg and <150/90 mmHg; Capable of providing a signed informed consent and comply with study requirements; Women with childbearing potential must have a negative pregnancy test (urine hCG) at spot urine at the screening visit and should use contraception during the study and until one week after completion of study treatment; Age ≥ 18 years; Good general health with no significant medical conditions or chronic illness (e.g., diabetes, hypertension, cardiovascular disease, autoimmune diseases, and cancer); Normal kidney function and no proteinuria at screening:; eGFR > 90 ml/min/1.73m2; U-ACR < 30 mg/g; Office blood pressure at the screening < 140/90 mmHg; Capable of providing a signed informed consent and comply with study requirements; Women with childbearing potential* must have a negative pregnancy test (urine hCG) at spot urine at the screening visit and should use contraception during the study and until one week after completion of study treatment.

Exclusion: Treatment with Amiloride, Spironolactone, Aldosterone, or analogues; Treatment with NSAIDs; Treatment with immunosuppressive therapy within 6 months prior to screening; Recent cardiovascular events < 2 months prior to screening:; Coronary artery revascularization; Acute stroke or TIA; Acute coronary syndrome; Treatment with any prescription medication except oral contraceptives; Use of NSAIDs (Non-Steroidal Anti-Inflammatory Drugs); Ongoing cancer treatment; History of organ transplantation; Evidence of current infection (CRP>50 or temperature > 38 C°); Severe hepatic insufficiency classified as Child-Pugh C; Congestive heart failure NYHA class IV, unstable or acute congestive heart failure; Allergy or hypersensitivity to the IMP; Addison's disease; Evidence of current infection (CRP>50 or temperature > 38 C°); History of substance abuse including alcohol; Allergy or hypersensitivity to the IMP; Hyperkalemia > 5.0 mmol/L at screening; P-bilirubin > 25 umol/L at screening; Hyperkalemia > 5.0 mmol/L at screening; P-bilirubin > 25 umol/L at screening; Breastfeeding; Gastric bypass operation; Lactose intolerance since lactose serves as one of the inactive ingredients in the IMP; Participation in other clinical trials within the last 30 days; Healthy controls:; Breastfeeding; Gastric bypass operation; Lactose intolerance since lactose serves as one of the inactive ingredients in the IMP; Participation in other clinical trials within the last 30 days.

Patients:.

ClinicalTrials.gov NCT06794593 · EU CTIS 2023-508516-34-00